LG Uplus, Kakao Mobility EV Charging Joint Venture Approved by the FTC 
Scotiabank Hires Morgan Stanley Executive to Lead Its Global Banking and Markets Unit 
Carlsberg Reports Strong Start to the Year with Premium Brand Growth 
LVMH succession planning: keeping it in the family when you’re the world’s richest man 
Spot Bitcoin ETFs Begin Trading in Hong Kong, Marking New Investment Era 
Philips Settles US Ventilator Recall Litigation for $1.1 Billion 
Philip Morris International Eyes Heated Tobacco Market Expansion in the US 
BTS Agency Hybe Demands Board Meeting, Ador CEO Rejects ‘Illegal’ Request 
Philippines' Binance Ban Leads to Spike in Trading Fees, Limited Crypto Access 
Vivendi Reveals Assessment to Split the Company is Ongoing 
KFC Dives Into Perfume Business, Introduces First-Ever BBQ Fragrance 
Paramount Ousts CEO Bob Bakish Amid Skydance Merger Talks 
Tesla Clears Regulatory Hurdles for FSD Launch in China with Baidu's Help 
Liverpool FC Expands into South Korea with First Retail Partnership 
Portugal Golden Visa as Best RCBI (Residency/ citizenship by investment) program in the world! 
Google Cuts Jobs in Key Programming Teams Before Developer Conference 
Ediya Coffee to Add Taiwanese QR Payment Option in May 
TEL AVIV, Israel, March 07, 2017 -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat central nervous system and cognitive disorders, today announced that management will participate in two upcoming investor healthcare conferences during March.
29th Annual ROTH Conference
Date: Tuesday, March 14
Time: 4:00 PM PDT
Location: Ritz Carlton Laguna Niguel, Orange County, CA
Oppenheimer 27th Annual Healthcare Conference
Date: Wednesday, March 22
Time: 9:45 AM EDT
Location: Westin Grand Central, New York, NY
About Alcobra
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of medications to treat CNS and cognitive disorders. For more information, please visit the company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
Investor Contacts Alcobra Investor Relations Debbie Kaye US: 212-390-8964, Intl: +972-3-7299871 [email protected]
